Asthma Management

AAAAI’s School Asthma and Allergy Bill Passes the House of Representatives | PRWeb | 9/30/2020

AAAAI’s School Asthma and Allergy Bill Passes the House of Representatives Share Article The bill, based on the AAAAI’s School-based Asthma Management Program (SAMPRO™), will now move on to the Senate. “The School-Based Allergies and Asthma Management Program Act (H.R. 2468) is important to encourage and support states in making sure schools have in place a comprehensive school-based allergies and asthma management program.” - AAAAI President Mary Beth …

ACTION ALERT: U.S. House of Representatives Passes H.R. 2468, the School-Based Allergies and Asthma Management Program Act | Allergy & Asthma Network | 9/29/2020

Advocacy , Allergies , Anaphylaxis , Asthma , News , School Allergy & Asthma Network today applauds the U.S. House of Representatives for passing the School-Based Allergies and Asthma Management Program Act, H.R. 2468 — but our work is not done! The legislation, long a priority for Allergy & Asthma Network and a host of health and patient organizations, now heads to the U.S. Senate for consideration. The Network will continue its advocacy efforts, urging passage of …

Hoyer Remarks on the School-Based Allergies and Asthma Management Program Act | 9/29/2020

MILWAUKEE , Sept. 29, 2020 /PRNewswire-PRWeb/ – The School-Based Allergies and Asthma Management Program Act (H.R. 2468), a bill supported by the American Academy of Allergy, Asthma & Immunology (AAAAI) that is based on the AAAAI’s School-based Asthma Management Program (SAMPRO™), has passed the House of Representatives by a voice vote and will now move on to the Senate for consideration. This bill would encourage schools receiving asthma-related grants …

Feinstein, Harder Urge Congress to Extend Deadline for Coronavirus Relief Funds | US Seante | 9/29/2020

… 4078 - EARLY Act Reauthorization of 2019 (Sponsored by Rep. Debbie Wasserman Schultz 14) H.R. 4996 - Helping MOMS Act of 2020, as amended (Sponsored by Rep. Robin Kelly 15) H.R. 2468 - School-Based Allergies and Asthma Management Program Steny Hoyer 16) H.R. 3131 - South Asian Heart Health Awareness and Research Act of 2020 (Sponsored by Rep. Pramila Jayapal 17) H.R. 5572 - Family Support Services for Addiction Act of 2020 (Sponsored by …

A Closer Look at Severe Asthma Over Time From Childhood | Physicians Weekly | 9/14/2020

… article/S0091-6749(19)31318-1/fulltext . McGeachie MJ, Yates KP, Zhou X, et al. Patterns of growth and decline in lung function in persistent childhood asthma. N Engl J Med . 2016;374:1842-1852. Global strategy for asthma management and prevention, updated 2018. Global Initiative for Asthma. Available at: https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-V1.3-002.pdf . Accessed January 10, 2020. Chipps BE, Haselkorn T, Paknis B, et al …

A Closer Look at Severe Asthma Over Time From Childhood | Physicians Weekly | 9/14/2020

… article/S0091-6749(19)31318-1/fulltext . McGeachie MJ, Yates KP, Zhou X, et al. Patterns of growth and decline in lung function in persistent childhood asthma. N Engl J Med . 2016;374:1842-1852. Global strategy for asthma management and prevention, updated 2018. Global Initiative for Asthma. Available at: https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-V1.3-002.pdf . Accessed January 10, 2020. Chipps BE, Haselkorn T, Paknis B, et al …

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US | 9/13/2020

… daily dose in an easy-to-use inhaler. The results from CAPTAIN were presented at the European Respiratory Society (ERS) Congress this week, reinforcing the potential of once-daily single inhaler triple therapy in asthma management . Pavel Raifeld, Chief Executive Officer of Innoviva, said: “In 2017, Trelegy Ellipta was approved in the US as the first once-daily single inhaler triple therapy for the treatment of COPD, and it remains …

AAAAI and NASN Release Guidance on Managing Food Allergies in Schools During COVID-19 | 9/11/2020

… nurses regarding food allergy management during COVID-19. This guidance comes on the heels of another document, School Attendance, Asthma and COVID-19 , which provides school nurses with a summary of overall recommendations for asthma management in schools during the pandemic. The new document covers important considerations for students with food allergies that are attending school in-person during COVID-19. Safe practices when it comes to food allergies are …

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US | Business Wire | 9/10/2020

… daily dose in an easy-to-use inhaler. The results from CAPTAIN were presented at the European Respiratory Society (ERS) Congress this week, reinforcing the potential of once-daily single inhaler triple therapy in asthma management . Pavel Raifeld, Chief Executive Officer of Innoviva, said: “In 2017, Trelegy Ellipta was approved in the US as the first once-daily single inhaler triple therapy for the treatment of COPD, and it remains …

Asthma Management Products Market Size, Growth Overview, SWOT Analysis & Forecast 2019-2023 | Wordpress.com | 9/10/2020

… causing symptoms such as coughing, shortness of breath, tightness, and wheezing. In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Asthma Management Products Report by Material, Application, and Geography – Global Forecast to 2023 is a professional and comprehensive research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and …

Electronic alert may reduce excessive prescribing of short-acting asthma relievers | 9/10/2020

… a 3-month period and then suggests an asthma review to assess symptoms and improve asthma control. Source: Adobe Stock. “While computer decision support is increasingly used to reduce high-risk prescribing and improve asthma management , the evidence to support the use of a simple single-component alert intervention in the identification and management of excessive SABA prescribing is unclear,” Shauna McKibben , PhD, allergy and asthma nurse specialist at Asthma …

AAAAI and NASN Release Guidance on Managing Food Allergies in Schools During COVID-19 | PRWeb | 9/10/2020

… nurses regarding food allergy management during COVID-19. This guidance comes on the heels of another document, School Attendance, Asthma and COVID-19 , which provides school nurses with a summary of overall recommendations for asthma management in schools during the pandemic. The new document covers important considerations for students with food allergies that are attending school in-person during COVID-19. Safe practices when it comes to food allergies are …

Asthma Management Products Market Size, Share, Opportunities And Strategies To 2023: COVID-19 Implications And Growth | Radiant Insights, Inc. | 9/9/2020

Radiant Insights, Inc. Asthma Management Products Market Huge Growth Opportunities Due To The COVID-19 Asthma Management Products Market Research Report 2019-2023 Asthma is a chronic disease, which cannot be cured only appropriate management is possible to control the disease. Asthma targets airways of the lungs causing it to inflame, swallow and tightens the airway of the lungs, causing respiratory tract infection and causing symptoms such as coughing, shortness of …

** | 9/9/2020**

… daily dose in an easy-to-use inhaler. The results from CAPTAIN were presented at the European Respiratory Society (ERS) Congress this week, reinforcing the potential of once-daily single inhaler triple therapy in asthma management . Pavel Raifeld, Chief Executive Officer of Innoviva, said: “In 2017, Trelegy Ellipta was approved in the US as the first once-daily single inhaler triple therapy for the treatment of COPD, and it remains …

** | 9/9/2020**

… daily dose in an easy-to-use inhaler. The results from CAPTAIN were presented at the European Respiratory Society (ERS) Congress this week, reinforcing the potential of once-daily single inhaler triple therapy in asthma management . Pavel Raifeld, Chief Executive Officer of Innoviva, said: “In 2017, Trelegy Ellipta was approved in the US as the first once-daily single inhaler triple therapy for the treatment of COPD, and it remains …

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US | Business & Finance | manchestertimes.com | Business Wire | 9/9/2020

… daily dose in an easy-to-use inhaler. The results from CAPTAIN were presented at the European Respiratory Society (ERS) Congress this week, reinforcing the potential of once-daily single inhaler triple therapy in asthma management . Pavel Raifeld, Chief Executive Officer of Innoviva, said: “In 2017, Trelegy Ellipta was approved in the US as the first once-daily single inhaler triple therapy for the treatment of COPD, and it remains …

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US - GuruFocus.com | 9/9/2020

… daily dose in an easy-to-use inhaler. The results from CAPTAIN were presented at the European Respiratory Society (ERS) Congress this week, reinforcing the potential of once-daily single inhaler triple therapy in asthma management . Pavel Raifeld, Chief Executive Officer of Innoviva, said: “In 2017, Trelegy Ellipta was approved in the US as the first once-daily single inhaler triple therapy for the treatment of COPD, and it remains …

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US - GuruFocus.com | 9/9/2020

… daily dose in an easy-to-use inhaler. The results from CAPTAIN were presented at the European Respiratory Society (ERS) Congress this week, reinforcing the potential of once-daily single inhaler triple therapy in asthma management . Pavel Raifeld, Chief Executive Officer of Innoviva, said: “In 2017, Trelegy Ellipta was approved in the US as the first once-daily single inhaler triple therapy for the treatment of COPD, and it remains …

Reimagining asthma care: how data and digital could bring asthma management goals within reach | 9/8/2020

… benefit from it. There is a great opportunity for patients with asthma to use new digital technologies and work together with physicians to increase adherence to their prescribed medication, helping them to achieve their asthma management goals. Helping to bring asthma management goals within reach There are certain rules of thumb in asthma management, such as following your treatment plan and consulting with your physician, which are generally advised. But …

Asthma in pregnancy by dr alka mukherjee dr apurva mukherjee nagpur m.s.india | 9/6/2020

… problem during pregnancy with up to 45% of women needing to seek medical help, resulting in poor outcomes for mothers and their babies, including low birth weight and preterm delivery. The goals of effective asthma management in pregnancy are to maintain the best possible asthma control and prevent exacerbations. This is achieved by aiming to prevent day- and night-time symptoms, and maintain lung function and normal activity. In addition …

Reimagining asthma care: how data and digital could bring asthma management goals within reach | 9/3/2020

… benefit from it. There is a great opportunity for patients with asthma to use new digital technologies and work together with physicians to increase adherence to their prescribed medication, helping them to achieve their asthma management goals. Helping to bring asthma management goals within reach There are certain rules of thumb in asthma management, such as following your treatment plan and consulting with your physician, which are generally advised. But …

T7 W7 PD1 R2 | 9/2/2020

… inhaled glucocorticoid for long term Asthma control of airway inflammation (Burchum & Rosenthal, 2019) Budesonide (Pulmicort Flexhaler) 360 -720 mcg bid will have few adverse effects and is an effective medication used in prophylaxis for asthma management . It is important to teach this patient to rinse and gargle with water after each use of the medication to avoid candidiasis or any speaking difficulty (Burchum & Rosenthal, 2019). She also needs to make …

Using Predictive Scoring Systems for Asthma Exacerbations Could Help Safely Conserve Resources During the COVID-19 Pandemic | 9/2/2020

A number of clinical scoring systems for asthma management have been described in the literature over the last four decades. 1 These systems are largely used to index severity of disease, quantify changes in disease status, and predict outcomes. Resulting scores can then be used to triage patients and guide therapy. Although they can be very useful tools, scoring systems are not perfect. To create a scoring system, one must …

GAAPP and AstraZeneca launch campaign to help asthma patients break over-reliance on their SABA ‘blue’ reliever inhaler to prevent asthma attacks | PR Newswire | 9/1/2020

… website featuring information that helps patients to take action, supports healthcare professionals to conduct ongoing treatment reviews, and encourages policymakers to identify mechanisms of change at the policy level to improve national standards of asthma management . The campaign provides an evidence-based digital tool, the Reliever Reliance Test at www.rateyourreliance.com , to assess a patient’s reliance on their SABA. The five-item questionnaire is adapted from the validated SABA Risk Questionnaire …

GAAPP and AstraZeneca launch campaign to help asthma patients break over-reliance on their SABA ‘blue’ reliever inhaler to prevent asthma attacks | Markets Insider | Business Insider | 9/1/2020

… website featuring information that helps patients to take action, supports healthcare professionals to conduct ongoing treatment reviews, and encourages policymakers to identify mechanisms of change at the policy level to improve national standards of asthma management . The campaign provides an evidence-based digital tool, the Reliever Reliance Test at www.rateyourreliance.com, to assess a patient’s reliance on their SABA. The five-item questionnaire is adapted from the validated SABA Risk Questionnaire …

Medicaid

Changing asthma inhaler devices abruptly may reduce lung function in children with asthma | PR Newswire | 10/14/2019

… the study findings at the CHEST Annual Meeting 2019 in New Orleans . Inhaled corticosteroid (ICS) therapy, a cornerstone of daily asthma management, is delivered by several types of inhalers that require different usage techniques. Insurance … ages 6 to 18 with asthma served by the impacted Medicaid plan from a large, university-based general pediatric clinic who had spirometry performed both before (February to July 2016 ) and after (February to July …

Gateway Health Celebrates 25th Anniversary | PR Newswire | 12/13/2017

PITTSBURGH , Dec. 12, 2017 /PRNewswire/ – Gateway Health, established in Pittsburgh in 1992, is celebrating 25 years of providing Medicaid health coverage to Pennsylvania residents and the city of Pittsburgh is honoring this achievement. Mayor Bill … both a positive and potentially lifesaving impact on residents including: asthma management, diabetes management, cardiovascular care, behavioral health care and substance abuse programs and care. Gateway Health has long recognized the ongoing health and social …

GSK

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US | Business Wire | 9/10/2020

LONDON & BURLINGAME, Calif.- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC … the potential of once-daily single inhaler triple therapy in asthma management. Pavel Raifeld, Chief Executive Officer of Innoviva, said: “In 2017, Trelegy Ellipta was approved in the US as the first once-daily single …

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US | Business & Finance | heraldchronicle.com | Business Wire | 9/9/2020

… COPD in the US Sep 9, 2020 Save LONDON & BURLINGAME, Calif.–(BUSINESS WIRE)–Sep 9, 2020– GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has … the potential of once-daily single inhaler triple therapy in asthma management. Pavel Raifeld, Chief Executive Officer of Innoviva, said: “In 2017, Trelegy Ellipta was approved in the US as the first once-daily single …

GlaxoSmithKline

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US | Business Wire | 9/10/2020

LONDON & BURLINGAME, Calif.- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC … the potential of once-daily single inhaler triple therapy in asthma management. Pavel Raifeld, Chief Executive Officer of Innoviva, said: “In 2017, Trelegy Ellipta was approved in the US as the first once-daily single …

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US | Business & Finance | heraldchronicle.com | Business Wire | 9/9/2020

… of Both Asthma and COPD in the US Sep 9, 2020 Save LONDON & BURLINGAME, Calif.–(BUSINESS WIRE)–Sep 9, 2020– GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and … the potential of once-daily single inhaler triple therapy in asthma management. Pavel Raifeld, Chief Executive Officer of Innoviva, said: “In 2017, Trelegy Ellipta was approved in the US as the first once-daily single …

Novartis

GSK, AstraZeneca, Genentech, and Novartis Identified as the Top Companies Driving Therapeutic Innovation in Asthma | PR Newswire | 3/18/2020

GSK, AstraZeneca, Genentech, and Novartis Identified as the Top Companies Driving Therapeutic Innovation in Asthma News provided by Mar 18, 2020, 14:00 ET Share this article MORRISTOWN, N.J. , March 18, 2020 /PRNewswire/ – In an ongoing … interleukine blockers/anti-IGE were the top therapeutic innovations in asthma management cited by those pulmonary disease specialists surveyed. Following GSK, which was cited by 60% of respondents as being best poised to drive future …

Inhaler devices and global warming: Flawed arguments | BMJ | 11/8/2019

… 2580&token=c87996bc2e26… . 13. Commissioned by the National Institute for Health and Care Excellence (NICE). Asthma: diagnosis, monitoring and chronic asthma management. NICE guideline [NG80] 2017 [Available from: https://www.nice.org.uk/guidance/ng80 14. Scottish Intercollegiate … International ,AstraZeneca, Orion,Trudell, Boeringer Ingelheim, Conzorcio Futuro In Ricerca, Novartis Pharmaceuticals, GLaxo Smith Klein , TEVA. Speaker fees from Teva, AstraZeneca, Chiesi, Orion, Menarini, Travel reimbursement for attending meetings from GINA, outside the submitted work …

Genentech

GSK, AstraZeneca, Genentech, and Novartis Identified as the Top Companies Driving Therapeutic Innovation in Asthma | PR Newswire | 3/18/2020

GSK, AstraZeneca, Genentech, and Novartis Identified as the Top Companies Driving Therapeutic Innovation in Asthma News provided by Mar 18, 2020, 14:00 ET Share this article MORRISTOWN, N.J. , March 18, 2020 /PRNewswire/ – In an ongoing … interleukine blockers/anti-IGE were the top therapeutic innovations in asthma management cited by those pulmonary disease specialists surveyed. Following GSK, which was cited by 60% of respondents as being best poised to drive future …

Abionic Signs Agreement to Optimize Asthma Management in the U.S. through Innovative Rapid Point-of-Care Tests | Business Wire | 9/5/2019

BIOPÔLE, LAUSANNE, Switzerland- Abionic SA , the developer of proprietary disruptive nanotechnology based rapid diagnostic solutions, and Genentech , a member of the Roche Group, announced today a strategic agreement to develop and provide an In Vitro Diagnostic (IVD) Asthma Test Panel using Abionic’s POC abioSCOPE ® platform in the United States. Abionic’s POC abioSCOPE ® , a compact, ultra-fast medical device powered by a patented nanofluidic technology, determines blood levels of immunoglobulin E …

Boehringer Ingelheim

Observational cohort study to investigate the unmet need and time waiting for referral for specialist opinion in adult asthma in England (UNTWIST asthma) | BMJ | 11/21/2019

… Gairdner Hospital , Nedlands , Western Australia , Australia 2 University of Liverpool Department of Health Services Research , Liverpool , UK 3 Market Access , Boehringer Ingelheim Ltd , Bracknell , UK 4 Medical Affairs , Boehringer Ingelheim Ltd , Bracknell , UK 5 Department … and quality of life. 2 3 One key aspect of asthma management is timely referral of patients with difficult-to-treat asthma for a specialist opinion. Patients receiving care from asthma specialists have relatively low …

Inhaler devices and global warming: Flawed arguments | BMJ | 11/8/2019

… 2580&token=c87996bc2e26… . 13. Commissioned by the National Institute for Health and Care Excellence (NICE). Asthma: diagnosis, monitoring and chronic asthma management. NICE guideline [NG80] 2017 [Available from: https://www.nice.org.uk/guidance/ng80 14. Scottish Intercollegiate … CCI has supplied inhaler training tools to GSK, Astra Zeneca, Boehringer Ingelheim, Teva, Menarini, Mundipharma, Napp, Chiesi, Novartis, Orion and Mylan. LF is an Asthma UK Senior Clinical Fellow. She reports fees for expert consultation …